 WALTHAM, Mass., Nov. 10, 2021 GLOBE NEWSWIRE -- Adagio Therapeutics, Inc., Nasdaq: ADGI a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences: 